Summary & Overview
HCPCS Level II J7331: Hyaluronan (Synojoynt) for Intra‑articular Injection, 1 mg
HCPCS Level II code J7331 identifies a 1 mg unit of hyaluronan derivative (Synojoynt) intended for intra‑articular injection. This product is used as a viscosupplement to address joint symptoms and is billed as a drug supply line item when administered directly into the joint space. Nationally, injectable intra‑articular products carry implications for outpatient drug benefit management, site‑of‑service billing, and prior authorization practices.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for intra‑articular hyaluronan, common billing and service settings, and the typical payer mix relevant to coverage and reimbursement discussions.
The publication outlines benchmarks such as standard billing practice for HCPCS drug codes, common modifier usage patterns (listed separately), and considerations for claim submission in outpatient and office settings. It also summarizes policy topics payers often address for intra‑articular biologics and injectables, including medical necessity criteria and documentation expectations. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J7331 represents hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg. This code denotes a single-unit injectable viscosupplement used for intra-articular treatment of joint conditions, administered by a clinician directly into the joint space.
Service Type: Intra-articular injectable medication
Typical Site of Service: Outpatient clinic, physician office, or ambulatory surgery center for joint injection procedures
Clinical & Coding Specifications
Clinical Context
A typical patient is a 55–75 year-old adult with symptomatic osteoarthritis of the knee who has persistent joint pain and functional limitation despite conservative measures (physical therapy, oral analgesics, topical agents, and intra-articular corticosteroid injections). The patient presents to an orthopedic clinic or ambulatory surgical center for an intra-articular hyaluronan derivative injection (J7331, synojoynt, 1 mg). The clinical workflow includes an evaluation by the ordering clinician (orthopedist, sports medicine physician, physiatrist, or rheumatologist), review of prior therapies and imaging (usually knee radiographs or MRI), informed consent specific to viscosupplementation, standard pre-injection skin antisepsis, optional local anesthetic, ultrasound or landmark-guided aspiration of effusion if present, and then intra-articular injection of the hyaluronan product. Post-procedure observation for immediate adverse reactions occurs in the clinic for a short interval. Documentation includes indication, laterality, volume/dose administered, lot number and product name, patient response, and any post-procedure instructions. Typical sites of service are outpatient clinic, office-based procedure room, or ambulatory surgical center. Common patient symptoms prompting this service include activity-related knee pain, morning stiffness less than 30 minutes, and decreased range of motion due to osteoarthritic joint changes.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JZ |